The industrial partnership program of the US state of Maryland (MIPS) awarded a grant for research of innovative technology created by Russian scientists.
The work conducted by several teams of researchers allowed the Russian Human Stem Cells Institute to develop and implement in practical healthcare Neovasculgen, the first gene-therapeutic drug in its class, and therapeutic angiogenesis (therapeutic growth of blood vessels), a method for treatment of ischemic diseases.
The essence of therapeutic angiogenesis is to start a genetically programmed process of formation and growth of blood vessels in ischemic tissue.
The grant was received by Artgen Inc., an American company whose shareholders include the Human Stem Cells Institute, and Brajesh Lal, professor at the University of Maryland. The grant was awarded to study the methods of assessing the clinical efficacy of gene therapy drug candidate based on the principle of therapeutic angiogenesis.
The studies led by professor Brajesh Lal will be aimed at developing additional visual criteria to assess the condition of the vascular bed and improve the blood flow in the ischemic limb as a result of neovascularization (formation and growth of collateral vessels). The obtained results will be subsequently used to effectively conduct clinical trials and registration of a gene therapy drug candidate that stimulates the therapeutic growth of blood vessels.